Paclitaxel-bevacizumab in Advanced Lung Cancer (Ultimate)
Phase III Study Comparing the Efficacy of Paclitaxel-bevacizumab With Docetaxel in 2nd or 3rd Line of Treatment of Non Squamous Non Small Cells Lung Cancer
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
A PHASE3 clinical study on Non-squamous Non-small Cell Lung Cancer, this trial is completed. The trial is conducted by Intergroupe Francophone de Cancerologie Thoracique and has accumulated 8 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Intergroupe Francophone de Cancerologie Thoracique
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Annemasse, France , Antony, France , Avignon, France , Bayonne, France , Bordeaux, France , Béziers, France , Caen, France , Castelnau, France , Chartres, France and 38 more locations